Reported Sunday, Aadi Bioscience Presented New Subgroup Analysis Of Patients With Advanced Malignant PEComa Of Gynecologic Origin Treated With Nab-Sirolimus At Society Of Gynecologic Oncology
Reported Sunday, Aadi Bioscience Presented New Subgroup Analysis Of Patients With Advanced Malignant PEComa Of Gynecologic Origin Treated With Nab-Sirolimus At Society Of Gynecologic Oncology
周日报道，Aadi Bioscience在妇科肿瘤学会发布了对接受Nab-Sirolimus治疗的晚期妇科恶性PECOMA患者的新亚组分析
- Subgroup experienced efficacy and safety consistent with overall study population
- Advanced malignant PEComa tumors of gynecologic origin accounted for more than half of the evaluable patients enrolled in AMPECT
- Additional data presented highlight nab-sirolimus as potential approach for mTOR-driven gynecologic cancers
- 亚组的疗效和安全性与总体研究人群一致
- 在参加AMPECT的可评估患者中，来自妇科的晚期恶性PeCOMA肿瘤占一半以上
- 提供的其他数据表明，nab-sirolimus是治疗MTOR驱动的妇科癌症的潜在方法